Generex releases positive data on Oral-lyn insulin replacement

By Elaine Rigoli

Tampa, Fla., May 2 - Generex Biotechnology Corp. said data from the initial 10 weeks of a six-month study showed the successful replacement of regular subcutaneous insulin with Generex Oral-lyn was achieved as demonstrated by patient-collected glucose levels, fructosamine and HbA1c measurements.

This data was presented at the Pediatric Academic Societies' 2006 annual meeting in San Francisco.

Also at the meeting, the company announced a podium presentation entitled "A 12-Day Comparison of Preprandial Humulin-R vs. Generex Oral-lyn in 10 Type-1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy."

The aim of this pilot study was to determine the suitability of dose and formulation of Generex Oral-lyn for its use in a larger multi-center trial, according to a news release.

The study also compared the glucodynamics of both rapid insulins (Generex Oral-lyn and Humulin-R) in 10 Type 1 diabetic subjects receiving glargine insulin as their baseline therapy.

Fructosamine, a parameter of protein glycation, was determined as part of a panel of safety monitoring, the release said.

Toronto-based Generex is engaged in the research and development of drug-delivery systems and technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.